2016 American Transplant Congress » Concurrent Session: SOT: HIV, HBV, & HCV

2:30pm-2:42pm

Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.

M. Aull, A. Watkins, J. Kim, K. Rhee, D. Dadhania, J. Lee, S. Kapur.

2:42pm-2:54pm

Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression.

M. Casey, T. Aijaz, X. Wen, S. Rehman, A. Santos, E. Thomas, K. Andreoni, K. Womer.

2:54pm-3:06pm

Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.

Y. Chang,^1,3 C. Chinchilla-Reyes,² M. Koss,^1,2 M. Nowicki.^1,2

3:06pm-3:18pm

Kidney Retransplantation Is Associated with Higher Mortality Risk Among HIV+ vs. HIV- Recipients.

B. Shelton,¹ S. Mehta,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Gustafson,³ C. Durand,⁴ D. Segev,⁴ J. Locke.¹

3:18pm-3:30pm

The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.

N. Polanco Fernandez,¹ A. García Santiago,¹ M. Fernández Ruiz,² R. Muñoz,³ C. Alvarez Vazquez,⁴ A. Hernandez,¹ V. Mercado,¹ E. González Monte,¹ I. Fernández,³ J. Aguado,² M. Praga,¹ A. Andres.¹

3:30pm-3:42pm

Efficacy and Safety of Direct Antiviral Agents (DAA)-Based Therapies for Hepatitis C Virus (HCV) Infection in Kidney Transplant (KT) Recipients.

M. Fernandez Ruiz,¹ A. García Santiago,² N. Polanco Fernandez,² R. Muñoz,³ A. Hernandez,² E. González Monte,² V. Mercado,² I. Fernández,³ J. Aguado,¹ M. Praga,² A. Andrés.²

3:42pm-3:54pm

Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.

B. Amundsen,¹ M. Sise,² M. Lin,³ H. Deirawan,¹ E. Heher,² B. Kimball,¹ J. Markmann,¹ N. Elias.¹